Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter Genes.
Front Genet., 3:248 (2012)
Discussion: a fresh look at monoamine oxidase inhibitors for depression.
J Clin Psychiatry., 73 Suppl 1:42-5 (2012)
Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update.
J Clin Psychiatry., 73 Suppl 1:17-24 (2012)
Literature based drug interaction prediction with clinical assessment using electronic medical records: novel myopathy associated drug interactions.
PLoS Comput. Biol., 8(8):e1002614 (2012)
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
J. Natl. Cancer Inst., Aug;104(16):1264; author reply 1266-8 (2012)
Reduced methadone clearance during aromatase inhibition.
J Clin Psychopharmacol., Aug;32(4):511-7 (2012)
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl-metabolites: exploration of a novel CYP2B6 phenotyping index.
Br J Clin Pharmacol., May (2012)
Pharmacogenetics and healthcare outcomes in patients with chronic heart failure.
Eur. J. Clin. Pharmacol., Nov;68(11):1483-91 (2012)
The need for translational research on drug-drug interactions.
Clin. Pharmacol. Ther., May;91(5):771-3 (2012)
Whole genome amplification of DNA for genotyping pharmacogenetics candidate genes.
Front Pharmacol., 3:54 (2012)
Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
Thromb. Res., Aug;130(2):198-202 (2012)
Influence of paraoxonase-1 Q192R and cytochrome P450 2C19 polymorphisms on clopidogrel response.
Clin Pharmacol., 4:13-20 (2012)
Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
Platelets., Mar (2012)
Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer.
J. Clin. Oncol., Mar;30(9):936-42 (2012)
Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.
Clin. Pharmacol. Ther., Mar;91(3):475-82 (2012)
In silico and in vitro identification of microRNAs that regulate hepatic nuclear factor 4Î± expression.
Drug Metab. Dispos., Apr;40(4):726-33 (2012)
A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese.
Hum. Mol. Genet., Apr;21(7):1665-72 (2012)
Comparison of Changes in the Lipid Profile of Postmenopausal Women With Early Stage Breast Cancer Treated With Exemestane or Letrozole.
J Clin Pharmacol., Dec;52(12):1852-1860 (2012)
A SNP in steroid receptor coactivator-1 disrupts a GSK3Î² phosphorylation site and is associated with altered tamoxifen response in bone.
Mol. Endocrinol., Feb;26(2):220-7 (2012)
Enhanced sensitivity to drug-induced QT interval lengthening in patients with heart failure due to left ventricular systolic dysfunction.
J Clin Pharmacol., Sep;52(9):1296-305 (2012)
Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer.
Breast Cancer Res. Treat., Feb;131(3):907-14 (2012)
Methadone adverse reaction presenting with large increase in plasma methadone binding: a case series.
J Med Case Rep., 5:513 (2011)
Functional characterization of a genetic polymorphism in the promoter of the ESR2 gene.
Horm Cancer., Apr;3(1-2):37-43 (2012)
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age.
Clin. Pharmacol. Ther., Nov;90(5):693-700 (2011)
Enantiomers of naringenin as pleiotropic, stereoselective inhibitors of cytochrome P450 isoforms.
Chirality., Sep (2011)
Stereoselective pharmacokinetics of stable isotope (+/-)-[(13) C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.
Chirality., Sep (2011)
Tamoxifen and its metabolites cause acute vasorelaxation of aortic rings by inducing vasodilator prostanoid synthesis.
J. Cardiovasc. Pharmacol., Dec;58(6):647-53 (2011)
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
Clin. Cancer Res., Nov;17(21):6944-51 (2011)
Cytochrome P450 polymorphisms and their relationship with premature ovarian failure in premenopausal women with breast cancer receiving doxorubicin and cyclophosphamide.
Breast J., 17(5):536-8 (2011 Sep-Oct)
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents.
Breast Cancer Res. Treat., May;133(1):99-109 (2012)
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study.
J. Clin. Oncol., Aug;29(24):3232-9 (2011)
Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy.
Clin Transl Sci., Jun;4(3):204-9 (2011)
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivity.
Diabetes Metab Syndr Obes., 4:99-105 (2011)
A modulated empirical Bayes model for identifying topological and temporal estrogen receptor Î± regulatory networks in breast cancer.
BMC Syst Biol., 5:67 (2011)
Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer.
Breast Cancer Res. Treat., Jan;131(2):473-81 (2012)
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
Br J Clin Pharmacol., Dec;70(6):854-69 (2010)
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation.
J. Natl. Cancer Inst., Nov;102(22):1698-705 (2010)
In vitro cytochrome P450-mediated metabolism of exemestane.
Drug Metab. Dispos., Jan;39(1):98-105 (2011)
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
J. Clin. Oncol., Nov;28(31):4674-82 (2010)
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results.
Clin. Pharmacol. Ther., Nov;88(5):626-9 (2010)
Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study.
Pharmacotherapy., Aug;30(8):787-96 (2010)
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study.
Br. J. Cancer., Jul;103(3):291-6 (2010)
Pharmacotherapy and pregnancy: highlights from the Second International Conference for Individualized Pharmacotherapy in Pregnancy.
Clin Transl Sci., Dec;2(6):439-43 (2009)
Differential quantification of CYP2D6 gene copy number by four different quantitative real-time PCR assays.
Pharmacogenet. Genomics., Jul;20(7):451-4 (2010)
Methadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).
Drug Metab. Dispos., Aug;38(8):1308-13 (2010)
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
Cancer Res., Apr;70(8):3278-86 (2010)
Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients.
J. Clin. Oncol., Mar;28(8):1287-93 (2010)
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients.
J Clin Pharmacol., Apr;50(4):450-8 (2010)
Identification of genetic variants in the human indoleamine 2,3-dioxygenase (IDO1) gene, which have altered enzyme activity.
Pharmacogenet. Genomics., Jun;19(6):464-76 (2009)
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.
Pharmacogenomics J., Aug;9(4):258-64 (2009)
Assessment of vascular effects of tamoxifen and its metabolites on the rat perfused hindquarter vascular bed.
Basic Clin. Pharmacol. Toxicol., May;104(5):400-7 (2009)
Clinically available pharmacogenomics tests.
Clin. Pharmacol. Ther., Jul;86(1):109-13 (2009)
Pharmacogenetics of tamoxifen: who should undergo CYP2D6 genetic testing?
J Natl Compr Canc Netw., Feb;7(2):203-13 (2009)
Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4'-methanol-bisbenzonitrile in vitro.
Cancer Chemother. Pharmacol., Oct;64(5):867-75 (2009)
Pharmacotherapy and pregnancy: Highlights from the first International Conference for Individualized Pharmacotherapy in Pregnancy.
Clin Transl Sci., Feb;2(1):11-4 (2009)
Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort.
Breast Cancer Res. Treat., Oct;117(3):571-5 (2009)
Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath test.
J. Pharmacol. Exp. Ther., Apr;329(1):297-305 (2009)
Estrogen receptor genotype is associated with risk of venous thromboembolism during tamoxifen therapy.
Breast Cancer Res. Treat., Jun;115(3):643-50 (2009)
Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
Pharmacotherapy., Dec;28(12):1461-70 (2008)
Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
J. Clin. Oncol., Dec;26(36):5849-54 (2008)
A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes.
J Biopharm Stat., 18(6):1150-77 (2008)
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans.
Pharmacogenomics., Oct;9(10):1445-58 (2008)
Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
Am J Psychiatry., Oct;165(10):1251-5 (2008)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
J. Clin. Oncol., Oct;26(28):4672-8 (2008)
Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Clin. Cancer Res., Sep;14(18):5864-8 (2008)
Exploratory study evaluating the association of polymorphisms of angiogenesis genes with hot flashes.
Breast Cancer Res. Treat., Aug;116(3):543-9 (2009)
Finding the right research question: quality science depends on quality careers.
Clin. Pharmacol. Ther., Sep;84(3):427-9 (2008)
Creating and evaluating genetic tests predictive of drug response.
Nat Rev Drug Discov., Jul;7(7):568-74 (2008)
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin.
Genet. Med., Feb;10(2):139-50 (2008)
Germline pharmacogenetics of tamoxifen response: have we learned enough?
J. Clin. Oncol., Nov;25(33):5147-9 (2007)
Association of polymorphisms of angiogenesis genes with breast cancer.
Breast Cancer Res. Treat., Sep;111(1):157-63 (2008)
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen.
Clin. Pharmacol. Ther., May;83(5):702-10 (2008)
The star-allele nomenclature: retooling for translational genomics.
Clin. Pharmacol. Ther., Sep;82(3):244-8 (2007)
Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Pharmacogenomics., Jun;8(6):547-58 (2007)
Drug-drug interaction prediction: a Bayesian meta-analysis approach.
Stat Med., Sep;26(20):3700-21 (2007)
The pharmacogenetics research network: from SNP discovery to clinical drug response.
Clin. Pharmacol. Ther., Mar;81(3):328-45 (2007)
Enhancing race-based prescribing precision with pharmacogenomics.
Clin. Pharmacol. Ther., Mar;81(3):323-5 (2007)
Pharmacogenomics: challenges and opportunities.
Ann. Intern. Med., Nov;145(10):749-57 (2006)
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Breast Cancer Res. Treat., Jan;101(1):113-21 (2007)
Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects.
Br J Clin Pharmacol., Feb;63(2):206-15 (2007)
Endothelial nitric oxide synthase haplotypes are related to blood pressure elevation, but not to resistance to antihypertensive drug therapy.
J. Hypertens., Dec;24(12):2393-7 (2006)
Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants.
Nat. Rev. Cancer., Nov;6(11):886-93 (2006)
Predicting asparaginase-associated pancreatitis.
Pediatr Blood Cancer., Oct;49(5):634-9 (2007)
The unfinished business of U.S. drug safety regulation.
Food Drug Law J., 61(1):45-63 (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment.
Clin. Pharmacol. Ther., Jul;80(1):61-74 (2006)
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
J. Pharmacol. Exp. Ther., Aug;318(2):503-12 (2006)
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodes.
Breast Cancer Res. Treat., Apr;96(3):209-15 (2006)
Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.
Oncologist., Feb;11(2):126-35 (2006)
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes.
J. Clin. Oncol., Dec;23(36):9312-8 (2005)
Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests.
Clin. Pharmacol. Ther., Dec;78(6):559-81 (2005)
CYP2D6 genotype and tamoxifen response.
Breast Cancer Res., 7(5):E6 (2005)
Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men.
Pharmacogenet. Genomics., Aug;15(8):565-70 (2005)
Effect of cirrhosis and liver transplantation on the gender difference in QT interval.
Am. J. Cardiol., Mar;95(5):691-4 (2005)
Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Cancer Chemother. Pharmacol., May;55(5):471-8 (2005)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
J. Natl. Cancer Inst., Jan;97(1):30-9 (2005)
Association between the CYP3A5 genotype and blood pressure.
Hypertension., Feb;45(2):294-8 (2005)
Creating incentives for genomic research to improve targeting of therapies.
Nat. Med., Dec;10(12):1289-91 (2004)
The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates.
J. Pharmacol. Exp. Ther., Mar;312(3):1144-50 (2005)
Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro.
Br J Clin Pharmacol., Sep;58(3):277-87 (2004)
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Drug Metab. Dispos., Sep;32(9):930-6 (2004)